Thiogenesis Therapeutics, Corp.

Biotechnology · TORONTO, A6

BiotechnologySEC Form D

Thiogenesis Therapeutics, Corp. filed a Form D with the U.S. Securities and Exchange Commission on June 9, 2026, reporting $28,964 raised.

Incorporated in Ontario, Canada and based in TORONTO, A6, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Thiogenesis Therapeutics, Corp. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Brook G. RigginsExecutive Officer · Director
  • Patrice RiouxExecutive Officer · Director
  • W. Hogan MullallyDirector
  • Kim TsuchimotoDirector
  • Christopher StarrDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$7.0MRaised

Ovelle Bio Corp.

BiotechnologyDOVER, DE
Jun 2, 2026View SEC Form D
$55.8MRaised

Contraline, Inc.

BiotechnologyCHARLOTTESVILLE, VA
May 29, 2026View SEC Form D
$22.9KRaised

Conexeu Sciences Inc.

BiotechnologyRENO, NV
May 28, 2026View SEC Form D
$100.0KRaised

Barricade Therapeutics Corp

BiotechnologyFORT WORTH, TX
May 27, 2026View SEC Form D
$1.2MRaised

SalivIQ Diagnostics Inc.

BiotechnologyHARRISONBURG, VA
May 26, 2026View SEC Form D